Analgesic and NSAID-induced Kidney Disease

Edited by

J.H. STEWART

Associate Dean, Western Clinical School
University of Sydney, Australia

Oxford New York Tokyo Melbourne
OXFORD UNIVERSITY PRESS
1993
## CONTENTS

List of contributors  xvi

1 Historical introduction  1
   'Phenacetin nephritis' in Switzerland  1
   Renal papillary necrosis in Scandinavia and Australia  2
       The association with urothelial cancer  2
   The pathology of analgesic nephropathy  3
   The aetiology of analgesic nephropathy  3
   Unanswered questions  4

2 The biochemistry and pharmacology of antipyretic–analgesics  5
   Aspirin and salicylate  5
       Chemistry  5
       Pharmacokinetics  6
       Mode of action  8
       Toxicity  9
   Paracetamol (acetaminophen)  9
       Pharmacokinetics  10
       Mechanism of action and pharmacological properties  12
       Toxicity  12
   Phenacetin  13
       Pharmacokinetics  13
       Action  14
       Toxicity  14
   Pyrazolons  15
       Pharmacology  15
   Conclusions  16

3 Experimental evidence for nephrotoxicity of analgesics  17
   Summary of experimental results  17
       Phenacetin  17
       Paracetamol  19
       Aspirin  22
Contents

Psychological aspects of drug use patterns 52
   Do consumers differ from non-consumers with regard to personality? 53
   Do groups of consumers with varying patterns of use differ? 55
Treatment and prevention 57

6 The analgesic syndrome 58
   Caffeine 60
      Withdrawal headache 60
      Direct caffeine toxicity 60
   Codeine 61
   Aspirin and salicylates 61
      Gastric ulcer 61
      Bleeding tendency 63
      Perinatal morbidity and mortality 63
   Phenacetin and paracetamol 64
      Cyanosis, haemolysis, and splenomegaly 64
      Pigmentation 64
   Pyrazolon derivatives 64
   Disorders of mixed or uncertain aetiology 64
      Central nervous system toxicity 64
      Accelerated atherogenesis 65
      Premature ageing 65
   A typical analgesic habitué 65

7 The pathology of analgesic nephropathy 67
   The lesions of analgesic-induced renal disease 67
      Capillary sclerosis 67
      Development of papillary necrosis 68
      The relationship of cortical change to papillary necrosis 74
      Fully developed analgesic nephropathy 77
   Pathogenesis of analgesic-induced lesions 79
   Specificity of the analgesic-induced lesion 80
   Complications of analgesic nephropathy 81
      Hypertension 81
      Pyelonephritis 81
      Obstruction 82
      Cysts 82
      Urothelioma 82
### Analgesic and NSAID-induced Kidney Disease

- Correlation between clinical presentation and morphology 82
- Cessation of analgesic abuse 83
- Concluding remarks 85

#### 8 The diagnosis of analgesic nephropathy by organ imaging

- Morphological features of analgesic nephropathy 86
  - Early signs 86
  - Partial papillary necrosis 86
  - Total papillary necrosis 88
  - Necrosis \textit{in situ} 88
  - The outcome of papillary sloughing 89
  - Parenchymal changes in analgesic nephropathy 89
  - Transitional cell carcinoma 89

#### Imaging techniques
- Pyelography 94
- Ultrasonography 95
- Computed tomography and plain film radiology 96

#### Differential diagnosis
- Normal kidney 98
- Calyceal cysts 98
- Reflux nephropathy (chronic pyelonephritis) 98
- Medullary sponge kidney 99
- Hydronephrotic atrophy 101
- Tuberculosis 101
- Metabolic nephrocalcinosis 101

#### 9 Functional defects in analgesic nephropathy

- Urinary abnormalities 102
  - Microscopy 102
  - Proteinuria 102
  - Acute urinary response to analgesic ingestion 103

- Renal dysfunction 103
  - Glomerular filtration rate 103
  - Tubular dysfunction 103

- Consequences of renal impairment 106
  - Hyperuricaemia 106
  - Hypertension 106
  - Renal osteodystrophy 107

- Effect of cessation of analgesic abuse 107
10 Clinical presentations of analgesic nephropathy 108
   Approach to the evaluation of patients 108
      Drug history 108
      Clinical examination 110
      Specific diagnosis of analgesic nephropathy 111
   Major clinical presentations 111
      Renal insufficiency 111
      Abnormal urinary findings 113
      Hypertension 113
      Papillary necrosis and calculus formation 114
      Urinary obstruction 114
   The value of renal biopsy 115
   Renal transplant failure 115
   Analgesic intake in patients with intrinsic renal disease 116
   Summary 117

11 Treatment of renal failure due to analgesics 119
   Prevention of further abuse 119
   Progression of analgesic nephropathy 121
      Discontinuation of analgesic intake 121
      Glomerulosclerosis 121
      Renal artery stenosis 121
      Acute renal failure 122
   Management of complications 123
      Urinary tract infections 123
      Salt-losing nephropathy 123
      Renal osteodystrophy 123
      Arterial hypertension 125
      Accelerated atherogenesis 125
      Anaemia 126
      Carcinoma 126
   Haemodialysis 127
      Acceptance for maintenance dialysis 127
   Renal transplantation 129
   Summary 131

12 Biochemistry and pharmacology of non-steroidal
   anti-inflammatory drugs and renal prostaglandins 133
      Biochemistry and distribution of renal eicosanoids 135
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Release of arachidonic acid</td>
<td>135</td>
</tr>
<tr>
<td>Oxidation of arachidonic acid</td>
<td>135</td>
</tr>
<tr>
<td>Degradation and elimination of eicosanoids</td>
<td>136</td>
</tr>
<tr>
<td>Renal distribution of eicosanoids</td>
<td>136</td>
</tr>
<tr>
<td>Synthesis and physiology of glomerular eicosanoids</td>
<td>137</td>
</tr>
<tr>
<td>Synthesis</td>
<td>137</td>
</tr>
<tr>
<td>Vasomotor action of glomerular eicosanoids</td>
<td>138</td>
</tr>
<tr>
<td>Modification of inflammatory responses by glomerular eicosanoids</td>
<td>139</td>
</tr>
<tr>
<td>Synthesis and physiology of tubular eicosanoids</td>
<td>139</td>
</tr>
<tr>
<td>Synthesis</td>
<td>139</td>
</tr>
<tr>
<td>Functions</td>
<td>139</td>
</tr>
<tr>
<td>Effects of local inhibition of cyclooxygenase</td>
<td>141</td>
</tr>
<tr>
<td>Inactivation of renal cyclooxygenase</td>
<td>142</td>
</tr>
<tr>
<td>Differential inhibition of human cyclooxygenase</td>
<td>143</td>
</tr>
<tr>
<td>Low dose aspirin</td>
<td>144</td>
</tr>
<tr>
<td>Sulindac</td>
<td>144</td>
</tr>
<tr>
<td>Tissue specific activities of non-steroidal anti-inflammatory drugs</td>
<td>145</td>
</tr>
<tr>
<td>Conclusions</td>
<td>146</td>
</tr>
<tr>
<td>13 Effects of non-steroidal anti-inflammatory drugs on renal function</td>
<td>147</td>
</tr>
<tr>
<td>Prostaglandins in the kidney</td>
<td>147</td>
</tr>
<tr>
<td>Modulatory role</td>
<td>147</td>
</tr>
<tr>
<td>Processes regulated by basal levels of prostaglandins</td>
<td>148</td>
</tr>
<tr>
<td>States associated with increased renal prostaglandin synthesis</td>
<td>148</td>
</tr>
<tr>
<td>The effect of prostaglandins on renal function</td>
<td>148</td>
</tr>
<tr>
<td>Renal haemodynamics</td>
<td>148</td>
</tr>
<tr>
<td>Glomerular function</td>
<td>149</td>
</tr>
<tr>
<td>Tubular processes</td>
<td>150</td>
</tr>
<tr>
<td>Endocrine effects</td>
<td>150</td>
</tr>
<tr>
<td>Renal effects of non-steroidal anti-inflammatory drugs</td>
<td>151</td>
</tr>
<tr>
<td>Normal individuals</td>
<td>151</td>
</tr>
<tr>
<td>Disease states</td>
<td>152</td>
</tr>
<tr>
<td>Special populations</td>
<td>154</td>
</tr>
<tr>
<td>Clinical syndromes resulting from non-steroidal anti-inflammatory drugs</td>
<td>154</td>
</tr>
<tr>
<td>Potassium, sodium, and water retention</td>
<td>156</td>
</tr>
<tr>
<td>Intrinsic kidney disease</td>
<td>156</td>
</tr>
</tbody>
</table>
Renal sparing non-steroidal anti-inflammatory drugs
  Sulindac
  Salicylates
Beneficial renal effects of non-steroidal anti-inflammatory drugs
Long term renal effects of non-steroidal anti-inflammatory drugs
Summary
Acknowledgements

14 Diseases of the kidney caused by non-steroidal anti-inflammatory drugs
  Incidence
  Acute interstitial nephritis
    Drugs involved
    Clinical features
    Pathology
    Diagnosis
    Pathogenesis
    Treatment
  Acute tubular necrosis
  Minimal change nephrotic syndrome
  Other glomerulopathies
    Membranous nephropathy
    Proliferative glomerulonephritis
  Papillary necrosis and chronic renal failure
  Other lesions
    Tubular obstruction
  Conclusions

15 Paracetamol-induced renal tubular cell necrosis
  Experimental evidence
    Histological findings in experimental animals
  Clinical observations
    Nephrotoxicity with no or little liver damage
  Clinical presentation
  Histological findings in patients
  Summary

16 Experimental evidence and the biochemical basis for the role of analgesics in cancer
  Urothelial tumours—induction and initiation
The aetiological role of analgesic abuse
  Phenacetin—an aetiological red herring
  Analgesics as carcinogens

Experimental models of renal papillary necrosis
  Papillotoxin-induced histochemical changes in renal papillae
  The probable mechanism of renal papillary necrosis
  Urothelial hyperplasia following renal papillary necrosis

Experimental models of upper urothelial carcinoma
  Spontaneous urothelial carcinoma
  One-stage models of upper urothelial carcinogenesis
  Two-stage models of upper urothelial carcinogenesis
  The relationship between renal papillary necrosis and upper urothelial cancer in man

Acknowledgements

Analgesics as human carcinogens—clinical and epidemiological evidence
  Case series
  Formal epidemiological evidence
    Case–control studies
    Cohort studies
    Summary of evidence implicating phenacetin or other analgesic drugs
    Evidence implicating renal papillary necrosis
    Population attributable risks
    Incidence of renal pelvic cancer
    Summary

Carcinoma of the renal pelvis
  Pathology
  Incidence
  Clinical aspects
    Diagnosis
    Treatment
    Prognosis

Prevention of analgesic-induced kidney disease
  The aetiology of analgesic-induced kidney disease
<table>
<thead>
<tr>
<th>Contents</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The conclusion based on epidemiological evidence</td>
<td>217</td>
</tr>
<tr>
<td>The conclusion based on laboratory evidence</td>
<td>218</td>
</tr>
<tr>
<td>Strategies for prevention</td>
<td>218</td>
</tr>
<tr>
<td>Prohibition of phenacetin (and paracetamol)</td>
<td>218</td>
</tr>
<tr>
<td>Restrictions on marketing compound analgesic preparations</td>
<td>219</td>
</tr>
<tr>
<td>Education and lobbying</td>
<td>219</td>
</tr>
<tr>
<td>Forces promoting continuance of analgesic consumption</td>
<td>220</td>
</tr>
<tr>
<td>The reality</td>
<td>221</td>
</tr>
<tr>
<td>Prevention of secondary renal damage</td>
<td>221</td>
</tr>
<tr>
<td>References</td>
<td>223</td>
</tr>
<tr>
<td>Index</td>
<td>285</td>
</tr>
</tbody>
</table>